Article
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
The Journal of experimental medicine - 7 Apr 2014
Berres Marie-Luise, Lim Karen Phaik Har, Peters Tricia, Price Jeremy, Takizawa Hitoshi, Salmon Hélène, Idoyaga Juliana, Ruzo Albert, Lupo Philip J, Hicks M John, Shih Albert, Simko Stephen J, Abhyankar Harshal, Chakraborty Rikhia, Leboeuf Marylene, Beltrão Monique, Lira Sérgio A, Heym Kenneth M, Bigley Venetia, Collin Matthew, Manz Markus G, McClain Kenneth, Merad Miriam, Allen Carl E
Abstract excerpt
Langerhans cell histiocytosis (LCH) is a clonal disorder with elusive etiology, characterized by the accumulation of CD207(+) dendritic cells (DCs) in inflammatory lesions. Recurrent BRAF-V600E mutations have been reported in LCH. In this study, lesions from 100 patients were genotyped, and 64% carried the BRAF-V600E mutation within infiltrating CD207(+) DCs. BRAF-V600E expression in tissue DCs did not define...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
